Sodium Sulfacetamide 10 Sulfur 5 Cleanser

Sulfacetamide Sodium And Sulfur


Acella Pharmaceuticals, Llc
Human Prescription Drug
NDC 42192-136
Sodium Sulfacetamide 10 Sulfur 5 Cleanser also known as Sulfacetamide Sodium And Sulfur is a human prescription drug labeled by 'Acella Pharmaceuticals, Llc'. National Drug Code (NDC) number for Sodium Sulfacetamide 10 Sulfur 5 Cleanser is 42192-136. This drug is available in dosage form of Rinse. The names of the active, medicinal ingredients in Sodium Sulfacetamide 10 Sulfur 5 Cleanser drug includes Sulfacetamide Sodium - 10 mg/g Sulfur - 5 mg/g . The currest status of Sodium Sulfacetamide 10 Sulfur 5 Cleanser drug is Active.

Drug Information:

Drug NDC: 42192-136
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Sulfacetamide 10 Sulfur 5 Cleanser
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sulfacetamide Sodium And Sulfur
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Acella Pharmaceuticals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Rinse
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SULFACETAMIDE SODIUM - 10 mg/g
SULFUR - 5 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 20 Apr, 2012
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Acella Pharmaceuticals, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:4NRT660KJQ
70FD1KFU70
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Sulfonamide Antibacterial [EPC]
Sulfonamides [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42192-136-06170.3 g in 1 BOTTLE (42192-136-06)20 Apr, 2012N/ANo
42192-136-08227 g in 1 BOTTLE (42192-136-08)19 Sep, 2016N/ANo
42192-136-12340.2 g in 1 BOTTLE (42192-136-12)20 Apr, 2012N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium sulfacetamide 10 sulfur 5 cleanser sulfacetamide sodium and sulfur butylated hydroxytoluene cetyl alcohol edetate disodium glyceryl monostearate peg-100 stearate magnesium aluminum silicate methylparaben propylparaben water sodium cocoyl isethionate sodium methyl cocoyl taurate sodium thiosulfate stearyl alcohol petrolatum xanthan gum sulfacetamide sodium sulfacetamide sulfur sulfur

Indications and Usage:

Indications: sodium sulfacetamide 10% - sulfur 5% cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

Warnings:

Warnings: although rare, sensitivity to sodium sulfacetaminde may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved.

General Precautions:

General - if irritation develops, use of the product should be discontinued and appropriate therapy instituted. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. the object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. these side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Dosage and Administration:

Dosage and administration: apply sodium sulfacetamide 10% - sulfur 5% cleanser once or twice daily to affected areas, or as directed by your physician. wet skin and liberally apply to areas to be cleansed. massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. if drying occurs, it may be controlled by rinsing off sodium sulfacetamide 10% - sulfur 5% cleanser sooner or using less often.

Contraindications:

Contraindications: sodium sulfacetamide 10% - sulfur 5% cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 10% - sulfur 5% cleanser is not to be used by patients with kidney disease.

Adverse Reactions:

Adverse reactions: although rare, sodium sulfacetamide may cause local irritation.

Use in Pregnancy:

Pregnancy: category c. animal reproduction studies have not been conducted with sodium sulfacetamide 10% - sulfur 5% cleanser. it is not known whether sodium sulfacetamide 10% - sulfur 5% cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. sodium sulfacetamide 10% - sulfur 5% cleanser should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use: safety and effectiveness in children under the age of 12 have not been established.

Description:

Description: each ml of sodium sulfacetamide 10% - sulfur 5% cleanser contains 100 mg of sodium sulfacetamide and 50 mg of sulfur in a formulation containing butylated hydroxytoluene, cetyl alcohol, disodium edta, glyceryl stearate, peg 100 stearate, magnesium aluminum silicate, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl taurate, sodium thiosulfate, stearyl alcohol, white petrolatum and xanthan gum. sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. chemically sodium sulfacetamide is n-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. the structural formula is: chemical structure

Clinical Pharmacology:

Clinical pharmacology: the most widely accepted mechanism of action of sulfonamides is the woods-fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (paba), an essential component for bacterial growth. while absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. the biological half-life has variously been reported as 7 to 12.8 hours. the exact mode of action of sulfur in the treatment of acne is not known, but it has been reported that it inhibits the growth of propionibacterium acnes and the formation of free fatty acids.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis and impairment of fertility - long-term studies in animals have not been performed to evaluate carcinogenic potential.

How Supplied:

How supplied: sodium sulfacetamide 10% - sulfur 5% topical suspension is available in 6 oz (170.3 g) bottles, ndc 42192-136-06, 8 oz (227 g) bottles, 42192-136-08 and 12 oz (340.2 g) bottles, ndc 42192-136-12. store at 15° - 25°c (59° - 77°f). protect from freezing. keep this and all medications out of the reach of children. all prescription substitutions using this product shall be made subject to state and federal statutes as applicable. note: this is not an orange book product and has not been subjected to fda therapeutic equivalency or other equivalency testing. no representation is made as to generic status or bioequivalency. each person recommending a prescription substitution using this product shall make such recommendations based on each such person’s professional opinion and knowledge, upon evaluating the active ingredients, excipients, inactive ingredients and chemical formulation information provided herein.

Information for Patients:

Information for patients - avoid contact with eyes, eyelids, lips and mucous membranes. if accidental contact occurs, rinse with water. if excessive irritation develops, discontinue use and consult your physician.

Package Label Principal Display Panel:

Principal display panel - 170.3 g bottle label ndc 42192-136-06 sodium sulfacetamide 10% - sulfur 5% cleanser rx only shake well before use 6 oz (170.3 g) acella pharmaceuticals, llc principal display panel - 170.3 g bottle label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.